Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cytosorbents Corp (CTSO)

49 + Investors. Track Smart Money conviction in CTSO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
46%

Smart Money Signals — CTSO

Based on 49 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
📊

High ownership — 94% of 3.0Y peak

94% of all-time peak
49 funds currently hold this stock — 94% of the 3.0-year high of 52 funds (reached 2023 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +11% more funds vs a year ago

fund count last 6Q
+5 new funds entered over the past year (+11% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 46% buying

19 buying22 selling
Last quarter: 22 funds reduced or exited vs 19 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~10 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 3 → 8 → 9 → 10. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

51% of holders stayed for 2+ years

■ 51% conviction (2yr+) ■ 20% medium ■ 29% new
25 out of 49 hedge funds have held CTSO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~10 new funds/quarter

4 → 3 → 8 → 9 → 10 new funds/Q
New funds entering each quarter: 3 → 8 → 9 → 10. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 55% veterans vs 29% newcomers

■ 55% veterans ■ 16% 1-2yr ■ 29% new
Entry-cohort mix of 49 holders: 27 (55%) are 2+ year veterans, 8 entered 1–2 years ago, and 14 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds
17 of 49 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CTSO

In 2026 Q1, 19 hedge funds were net buyers of CTSO (10 opened a new position, 9 added to an existing one), while 22 reduced or exited (12 trimmed, 10 sold completely) — a 46% buyer ratio, indicating roughly balanced activity. 23% of total institutional value in CTSO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 49.

Hedge Fund Ownership: CTSO

How many hedge funds hold CTSO — quarterly history vs. share price
Quarterly hedge fund ownership of CTSO vs. share price

Market Analysis: CTSO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CTSO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cytosorbents Corp (CTSO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CTSO has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
CTSO
+7.0%
XLV
+5.5%

CTSO outperformed XLV by +1.5% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
CTSO
+0.0%
XLV
+0.0%

Since the filing became public, CTSO outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

5 top-rated funds 0 high-conviction
Consensus
3.4
/ 10
breadth
×
Elite
0.4
/ 10
conviction
Hedge Fund Positioning: CTSO
2026 Q2 Stats Unlock in 3 days 49 + Investors

Track Smart Money conviction in CTSO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 49 48 2.08%
13F Shares 16M 17M -2.37%
Total Value $9M $11M -13.54%
New Positions 10 8 +2
Increased Positions 9 14 -5
Closed Positions 9 7 +2
Reduced Positions 12 10 +2
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: CTSO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

49 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CTSO. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 CTSO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 CM Management, LLC 0.35% 1,476,500 $552K
2 Avenir Corp 0.24% 5,189,218 $1.9M
3 Skylands Capital, LLC 0.06% 1,211,400 $453K
4 Sargent Investment Group, LLC 0.02% 555,757 $208K
5 Key Client Fiduciary Advisors, LLC 0.01% 78,457 $29K
6 Seelaus Asset Management LLC 0.00% 16,300 $6K
7 NWF Advisory Services Inc. 0.00% 104,139 $39K
8 Marathon Capital Management 0.00% 10,000 $4K
9 Pathstone Holdings, LLC 0.00% 499,910 $187K
10 Neuberger Berman Group LLC 0.00% 1,968,691 $741K
11 Sfmg, LLC 0.00% 20,000 $7K
12 XTX Topco Ltd 0.00% 54,316 $20K
13 First National Bank of Omaha 0.00% 15,225 $6K
14 Ritholtz Wealth Management 0.00% 27,443 $10K
15 Tower Research Capital LLC (TRC) 0.00% 10,223 $4K
16 CIBC Bancorp USA Inc. 0.00% 172,649 $65K
17 Osaic Holdings, INC. 0.00% 134,839 $50K
18 Renaissance Technologies LLC 0.00% 100,020 $37K
19 EP Wealth Advisors, LLC 0.00% 28,000 $10K
20 Merit Financial Group, LLC 0.00% 15,297 $6K
21 Kestra Advisory Services, LLC 0.00% 28,200 $11K
22 Vanguard Fiduciary Trust Co 0.00% 316,167 $118K
23 Hrt Financial LP 0.00% 32,125 $12K
24 Vanguard Capital Management LLC 0.00% 1,914,063 $716K
25 Stifel Financial Corp 0.00% 48,000 $18K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cytosorbents Corp (CTSO)

What does the Smart Money Trend signal show for CTSO?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for CTSO?

More sellers than buyers — 46% buying: Last quarter: 22 funds reduced or exited vs 19 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for CTSO holders?

Strong quality — 23% AUM from major funds: 17 of 49 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CTSO?

51% of holders stayed for 2+ years: 25 out of 49 hedge funds have held CTSO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cytosorbents Corp (CTSO) following the 2026 Q2 hedge fund 13F filings?

As of today, CTSO has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CTSO has gained +7.0% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →